Periodontitis and Systemic Diseases

195.Zizzi A, Tirabassi G, Aspriello SD, Piemontese M, Rubini C, Lucarini G. Gingival advanced glycation end-products in diabetes mellitus-associated chronic periodontitis: an immunohistochemical study. J Periodontal Res 2013; 48:293–301.

196.Lalla E, Lamster IB, Feit M, et al. Blockade of RAGE suppresses periodontitis-associated bone loss in diabetic mice. J Clin Invest 2000;105:1117–1124.

197.Chang PC, Chien LY, Chong LY, Kuo YP, Hsiao JK. Glycated matrix up-regulates inflammatory signaling similarly to Porphyromonas gingivalis lipopolysaccharide. J Periodontal Res 2013;48:184–193.

198.Aemaimanan P, Amimanan P, Taweechaisupapong S. Quantification of key periodontal pathogens in insulin-dependent type 2 diabetic and non-diabetic patients with generalized chronic periodontitis. Anaerobe 2013; 22:64–68.

199.Demmer RT, Jacobs DR Jr, Singh R, et al. Periodontal bacteria and prediabetes prevalence in ORIGINS. J Dent Res 2015;94:201S–211S.

200.Chang LC, Kuo HC, Chang SF, et al. Regulation of ICAM-1 expression in gingival fibroblasts infected with high-glucose-treated P. gingivalis . Cell Microbiol 2013;15: 1722–1734.

201.Merchant AT, Shrestha D, Chaisson C, Choi YH, Hazlett LJ, Zhang J. Association between serum antibodies to oral microorganisms and hyperglycemia in adults. J Dent Res 2014;93:752–759.

202.Sakalauskiene J, Kubilius R, Gleiznys A, Vitkauskiene A, Ivanauskiene E, Šaferis V. Relationship of clinical and microbiological variables in patients with type 1 diabetes mellitus and periodontitis. Med Sci Monit 2014;20: 1871–1877.

203.Liu LS, Gkranias N, Farias B, Spratt D, Donos N. Differences in the subgingival microbial population of chronic periodontitis in subjects with and without type 2 diabetes mellitus-a systematic review. Clin Oral Investig 2018;22:2743–2762.

204.Börgeson E, Godson C. Resolution of inflammation: Therapeutic potential of pro-resolving lipids in type 2 diabetes mellitus and associated renal complications. Front Immunol 2012;3:318.

205.Serhan CN. Systems approach to inflammation resolution: identification of novel anti-inflammatory and pro-­resolving mediators. J Thromb Haemost 2009;7(Suppl 1): 44–48.

206.El Kebir D, Gjorstrup P, Filep JG. Resolvin E1 promotes phagocytosis-induced neutrophil apoptosis and accelerates resolution of pulmonary inflammation. Proc Natl Acad Sci U S A 2012;109:14983–14988.

207.Oh SF, Pillai PS, Recchiuti A, Yang R, Serhan CN. Pro-resolving actions and stereoselective biosynthesis of 18S E-series resolvins in human leukocytes and murine inflammation. J Clin Invest 2011;121:569–581.

208.Serhan CN, Yacoubian S, Yang R. Anti-inflammatory and proresolving lipid mediators. Annu Rev Pathol 2008;3: 279–312.

209.Serhan CN, Savill J. Resolution of inflammation: The beginning programs the end. Nat Immunol 2005;6:1191–1197.

210.Gyurko R, Siqueira CC, Caldon N, Gao L, Kantarci A, Van Dyke TE. Chronic hyperglycemia predisposes to exaggerated inflammatory response and leukocyte dysfunction in Akita mice. J Immunol 2006;177:7250–7256.

211.Wierusz-Wysocka B, Wysocki H, Siekierka H, Wykretowicz A, Szczepanik A, Klimas R. Evidence of polymorphonuclear neutrophils (PMN) activation in patients with insulin-dependent diabetes mellitus. J Leukoc Biol 1987;42:519–523.

212.Serhan CN, Hong S, Gronert K, et al. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med 2002;196:1025–1037.

213.Aoki H, Hisada T, Ishizuka T, et al. Resolvin E1 dampens airway inflammation and hyperresponsiveness in a murine model of asthma. Biochem Biophys Res Commun 2008;367:509–515.

214.Tian H, Lu Y, Sherwood AM, Hongqian D, Hong S. Resolvins El and Dl in choroid-retinal endothelial cells and leukocytes: Biosynthesis and mechanisms of anti-inflammatory actions. Invest Ophthalmol Vis Sci 2009;50: 3613–3620.

215.Gao L, Faibish D, Fredman G, et al. Resolvin E1 and chemokine-like receptor 1 mediate bone preservation. J Immunol 2013;190:689–694.

216.Herrera BS, Ohira T, Gao L, et al. An endogenous regulator of inflammation, resolvin E1, modulates osteoclast differentiation and bone resorption. Br J Pharmacol 2008;155:1214–1223.

217.Hasturk H, Kantarci A, Goguet-Surmenian E, et al. Resolvin E1 regulates inflammation at the cellular and tissue level and restores tissue homeostasis in vivo. J Immunol 2007;179:7021–7029.

218.Herrera BS, Hasturk H, Kantarci A, et al. Impact of resolvin E1 on murine neutrophil phagocytosis in type 2 diabetes. Infect Immun 2015;83:792–801.

219.Freire MO, Dalli J, Serhan CN, Van Dyke TE. Neutrophil resolvin E1 receptor expression and function in type 2 diabetes. J Immunol 2017;198:718–728.

220.Grover HS, Luthra S. Molecular mechanisms involved in the bidirectional relationship between diabetes mellitus and periodontal disease. J Indian Soc Periodontol 2013;17:292–301.

221.Sanz M, Ceriello A, Buysschaert M, et al. Scientific evidence on the links between periodontal diseases and diabetes: Consensus report and guidelines of the joint workshop on periodontal diseases and diabetes by the International Diabetes Federation and the European Federation of Periodontology. J Clin Periodontol 2018;45: 138–149.

222.Nasseh K, Vujicic M, Glick M. The relationship between periodontal interventions and healthcare costs and utilization. evidence from an integrated dental, medical, and pharmacy commercial claims database. Health Econ 2017;26:519–527.

223.Albert DA, Ward A, Allweiss P, et al. Diabetes and oral disease: Implications for health professionals. Ann N Y Acad Sci 2012;1255:1–15.

Further reading (recently published literature)

Cirelli T, Nepomuceno R, Rios ACS, et al. Genetic polymorphisms in the Interleukins IL1B, IL4, and IL6 are associated with concomitant periodontitis and type 2 diabetes mellitus in Brazilian patients. J Periodontal Res 2020;55:918–930.

Isola G, Matarese G, Ramaglia L, Pedullà E, Rapisarda E, Iorio-Siciliano V. Association between periodontitis and glycosylated haemoglobin before diabetes onset: a cross-sectional study. Clin Oral Investig 2020;24:2799–2808.

Baeza M, Morales A, Cisterna C, et al. Effect of periodontal treatment in patients with periodontitis and diabetes: systematic review and meta-analysis. J Appl Oral Sci 2020;28: e20190248.

Preshaw PM, Taylor JJ, Jaedicke KM, et al. Treatment of periodontitis reduces systemic inflammation in type 2 diabetes. J Clin Periodontol 2020;47:737–746.

Wu CZ, Yuan YH, Liu HH, et al. Epidemiologic relationship between periodontitis and type 2 diabetes mellitus. BMC Oral Health 2020;20:204.

Xu J, Duan X. Association between periodontitis and hyperlipidaemia: A systematic review and meta-analysis. Clin Exp Pharmacol Physiol 2020;47:1861–1873.

Gomes-Filho IS, Balinha IDSCE, da Cruz SS, et al. Moderate and severe periodontitis are positively associated with metabolic syndrome (Epub ahead of print, 23 Nov 2020). Clin Oral Investig doi: 10.1007/s00784-020-03699-2.

Montero E, Molina A, Carasol M, et al. The association between metabolic syndrome and periodontitis in Spain: Results from the WORALTH (Workers’ ORAL healTH) Study. J Clin Periodontol 2021;48:37–49.

Cirelli T, Nepomuceno R, Goveia JM, et al. Association of type 2 diabetes mellitus and periodontal disease susceptibility with genome-wide association-identified risk variants in a Southeastern Brazilian population (Epub ahead of print, 3 Jan 2021). Clin Oral Investig doi: 10.1007/s00784-020-03717-3.

Текст предоставлен ООО «ЛитРес».

Прочитайте эту книгу целиком, купив полную легальную версию на ЛитРес.